Recent Updates
Recently added Catalysts
IMMP

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B +Rule 4.7B Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Friday, October 21, 2016 1 min read
Key Takeaway: Quarterly report for entities subject to Listing Rule 4.7B for entities subject to Listing Rule 4.7B Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16 Name of entity Prima BioMed Limited ABN Quarter ended ( current quarter ) 90 009 237 889 30 th September 2

Full Press Release Details

Quarterly report for entities
subject to Listing Rule 4.7B
for entities subject to Listing Rule 4.7B
Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16
Name of entity
Prima BioMed Limited
ABN Quarter ended ( current quarter )
90 009 237 889 30 th September 2016
Consolidated statement of cash flows Current quarter $A 000 Year to date (3 months) $A 000
1. Cash flows from operating activities
1.1 Receipts from customers 56 56
1.2 Payments for
(a) research and development (1,069 ) (1,069 )
(b) product manufacturing and operating costs
(c) advertising and marketing (82 ) (82 )
(d) leased assets
(e) staff costs (708 ) (708 )
(f) administration and corporate costs (711 ) (711 )
1.3 Dividends received (see note 3)
1.4 Interest received 36 36
1.5 Interest and other costs of finance paid
1.6 Income taxes paid
1.7 Government grants and tax incentives
1.8 Other (provide details if material)
1.9 Net cash from / (used in) operating activities (2,478 ) (2,478 )
2. Cash flows from investing activities
2.1 Payments to acquire:
(a) property, plant and equipment
(b) businesses (see item 10)
(c) investments
+ See chapter 19 for defined terms
1 September 2016 Page 1
Quarterly report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows Current quarter $A 000 Year to date (3 months) $A 000
(d) intellectual property
(e) other non-current assets
2.2 Proceeds from disposal of:
(a) property, plant and equipment
(b) businesses (see item 10)
(c) investments
(d) intellectual property
(e) other non-current assets
2.3 Cash flows from loans to other entities
2.4 Dividends received (see note 3)
2.5 Other (provide details if material)
2.6 Net cash from / (used in) investing activities
3. Cash flows from financing activities
3.1 Proceeds from issues of shares
3.2 Proceeds from issue of convertible notes
3.3 Proceeds from exercise of share options
3.4 Transaction costs related to issues of shares, convertible notes or options
3.5 Proceeds from borrowings
3.6 Repayment of borrowings
3.7 Transaction costs related to loans and borrowings
3.8 Dividends paid
3.9 Other (provide details if material)
3.10 Net cash from / (used in) financing activities
4. Net increase / (decrease) in cash and cash equivalents for the period
4.1 Cash and cash equivalents at beginning of quarter/year to date 20,880 20,880
4.2 Net cash from / (used in) operating activities (item 1.9 above) (2,478 ) (2,478 )
4.3 Net cash from / (used in) investing activities (item 2.6 above)
4.4 Net cash from / (used in) financing activities (item 3.10 above)
+ See chapter 19 for defined terms
1 September 2016 Page 2
Quarterly report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows Current quarter $A 000 Year to date (3 months) $A 000
4.5 Effect of movement in exchange rates on cash held (216 ) (216 )
4.6 Cash and cash equivalents at end of quarter 18,186 18,186
Current quarter $A 000 Previous quarter $A 000
5. Reconciliation of cash and cash equivalents
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts
5.1 Bank balances 11,165 12,993
5.2 Call deposits 6,760 7,627
5.3 Bank overdrafts
5.4 Other (provide details) 261 260
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 18,186 20,880
Current quarter $A 000
6. Payments to directors of the entity and their associates
6.1 Aggregate amount of payments to these parties included in item 1.2 163
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2
Directors fees and consulting fees at normal commercial rates
Current quarter $A 000
7. Payments to related entities of the entity and their associates
7.1 Aggregate amount of payments to these parties included in item 1.2
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2
+ See chapter 19 for defined terms
1 September 2016 Page 3
Quarterly report for entities subject to Listing Rule 4.7B
Total facility amount at quarter end $A 000 Amount drawn at quarter end $A 000
8. Financing facilities available Add notes as necessary for an understanding of the position
8.1 Loan facilities
8.2 Credit standby arrangements
8.3 Other (please specify)
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.
$A 000
9. Estimated cash outflows for next quarter
9.1 Research and development 2,242
9.2 Product manufacturing and operating costs
9.3 Advertising and marketing 63
9.4 Leased assets
9.5 Staff costs 733
9.6 Administration and corporate costs 824
9.7 Other (provide details if material)
9.8 Total estimated cash outflows 3,862
Acquisitions Disposals
10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)
10.1 Name of entity
10.2 Place of incorporation or registration
10.3 Consideration for acquisition or disposal
10.4 Total net assets
10.5 Nature of business
+ See chapter 19 for defined terms
1 September 2016 Page 4
Quarterly report for entities subject to Listing Rule 4.7B
Compliance statement
Company Secretary
Print name: Tom Bloomfield
+ See chapter 19 for defined terms
1 September 2016 Page 5
Tags: IMMP Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 21, 2016